Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

70.250
-1.650-2.29%
Volume:2.45M
Turnover:175.39M
Market Cap:39.59B
PE:46.53
High:74.800
Open:73.600
Low:70.100
Close:71.900
52wk High:124.000
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:2.21
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.510
ROE:109.10%
ROA:39.01%
PB:4.07
PE(LYR):46.53
PS:4.23

Loading ...

Citi Lifts REMEGEN Price Target to HK$127.7, Keeps Buy/High-Risk Call

Stock News
·
Aug 26

CLSA Raises REMEGEN Price Target to HK$144.8, Reiterates Outperform Rating on Strong Q2 Beat

Stock News
·
Aug 26

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Movement Alert|REMEGEN Rises 5.04% in Regular Trading, Interim Results Turn Profitable Amid Biotech Sector Rally

Market Focus
·
Aug 26

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

Movement Alert|REMEGEN Rises 5.12% in Regular Trading, H1 Earnings Show Turnaround to Profitability with Revenue Surging Over 4x

Market Focus
·
Aug 25

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live
·
Aug 25

RemeGen turns profitable: H1 2026 revenue jumps 435.74% to RMB5.85 billion on AbbVie deal and core drug sales

Bulletin Express
·
Aug 24

Movement Alert|REMEGEN Falls 5.13% in Regular Trading, Market Questions Sustainability of One-Time Licensing Revenue Ahead of Interim Results

Market Focus
·
Aug 24

Movement Alert|REMEGEN Rises 5.2% in Regular Trading, Biotech Sector Rallies Ahead of Interim Results Release

Market Focus
·
Aug 20

RemeGen commits an additional US$30.00 million to OCBC structured deposit; aggregate wealth-management investment reaches US$100.00 million

Bulletin Express
·
Aug 18

Earning Preview: REMEGEN Q2 revenue is expected to increase by 691%, and institutional views are bullish

Earnings Agent
·
Aug 17

Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal

Stock Track
·
Aug 10

Movement Alert|REMEGEN Rises 3.88% in Regular Trading, H1 Earnings Preview Shows Turnaround to Profitability with 47 Billion Yuan Net Profit

Market Focus
·
Aug 10

Hong Kong Stocks in Focus: Remegen Surges Over 5% Before Noon, Achieves First Major Mid-Term Profit Driven by Overseas Licensing

Stock News
·
Aug 07

Movement Alert|REMEGEN Rises 5.03% in Regular Trading, H1 Earnings Swing to Profit with Essential Drug Catalog Catalyst

Market Focus
·
Aug 07

RemeGen Expects to Return to Profit in H1; Hong Kong Shares Down 3%

MT Newswires Live
·
Aug 06

Hong Kong Stock Moves: Remegen Opens Nearly 4% Higher, Anticipates First-Half Net Profit Attributable to Parent of Approximately 4.7 Billion Yuan

Stock News
·
Aug 06

RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge

Bulletin Express
·
Aug 05

RemeGen’s July 2026 Share Update: H-Share Base Steady, A-Share Buyback Trims Free Float by 13,000 Shares

Bulletin Express
·
Aug 04